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Abstract
Background High-risk alcohol use is correlated with chronic pain. Chronic pain and alcohol dependence 
are associated with similar neurological, endocrinological and behavioural patterns, and it has been 
hypothesised that symptoms of neuropathic pain are exacerbated following alcohol withdrawal. 
Aim To investigate the presence of neuropathic pain upon withdrawal from alcohol, in people with high-
risk alcohol use with or without a history of medically assisted detoxification. 
Method A small observational cross-sectional study investigated the presence of neuropathic pain in 
two groups of hospitalised adults exhibiting high-risk alcohol use: one group with a history of medically 
assisted detoxification, the other group with no history of medically assisted detoxification. 
Results The results provided some evidence that neuropathic pain is more likely to be experienced by 
people with high-risk alcohol use who have previously undergone medically assisted detoxification. 
Conclusion Understanding that previous medically assisted detoxification may increase the risk of 
neuropathic pain means that nurses can improve their preparation when assessing, monitoring and 
managing neuropathic pain in people recovering from high-risk alcohol use. Nurses will be able to 
direct patients recovering from high-risk alcohol use to available pain management support in a timely 
manner, for example a local pain clinic, possibly even before detoxification. This is important given the 
links between pain, relapse into alcohol use and addiction to analgesics. 
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Background
As many as 10.8 million adults in the UK 
consume alcohol at levels that pose a risk to 
health, while 1.6 million ‘may have some level’ 
of dependence on alcohol, which means they are 
likely to experience withdrawal symptoms upon 
alcohol cessation (Public Health England (PHE) 
2016). High-risk alcohol use describes a pattern 
of alcohol consumption that causes mental or 
physical damage (National Institute for Health 
and Clinical Excellence (NICE 2011). High-risk 
alcohol use is also correlated with chronic pain 
and suboptimal pain outcomes (Zale et al 2015). 
Egli et al (2012) hypothesised that chronic pain 
and alcohol dependence are associated with 
similar neurological and hormonal profiles and 
that neuropathic pain symptoms can present in 
people who withdraw from alcohol.
Relationship between pain and alcohol
According to the International Association for 
the Study of Pain (IASP), pain is ‘an unpleasant 
sensory and emotional experience associated 
with, or resembling that associated with, actual 
or potential tissue damage’ (Raja et al 2020). 
The IASP adds that ‘pain is always a personal 
experience that is influenced to varying degrees 
by biological, psychological, and social factors’ 
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Why you should read this article:
● To understand the association between neuropathic pain and high-risk alcohol use
● To learn how chronic pain can develop on withdrawal from alcohol
● To familiarise yourself with the concept that previous medically assisted detoxification may increase the risk
of neuropathic pain
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(Raja et al 2020). Perceptions 
of pain are also characterised by 
factors beyond the pain stimulus 
itself, such as mood, cognition and 
culture (Moayedi and Davis 2013). 
Between one third and one half of 
the UK population live with chronic 
pain (Fayaz et al 2016). 
The term ‘neuropathic pain’ 
describes ‘pain caused by a lesion 
or disease of the somatosensory 
nervous system’ (IASP 2017). 
People describe neuropathic pain 
as ‘burning’, ‘tingling’, ‘numbness’ 
or resembling an ‘electric shock’ 
(Callin and Bennett 2008). 
Neuropathic pain can arise from 
lesions or diseases that affect 
the nervous system, such as 
diabetes mellitus, vasculitis, stroke 
and certain genetic conditions 
(IASP 2017). It can also arise 
from alcohol-related peripheral 
neuropathy, a potentially significant 
and debilitating complication of 
alcohol use thought to be caused 
by alcohol’s toxic effects (Mellion 
et al 2011). 
Although alcohol has some 
analgesic effect (Thompson et al 
2017), high-risk alcohol use  
is associated with suboptimal  
pain outcomes (Zale et al 2015), 
and increases the risk of an 
individual developing painful 
peripheral neuropathy (Chopra  
and Tiwari 2012). 
In terms of public health, alcohol 
causes wide-ranging health, social 
and/or economic harm (PHE 
2018). Alcohol consumption 
involves direct costs to the health, 
social care, criminal justice, and 
unemployment and welfare systems, 
and incurs indirect social costs 
through lost productivity due 
to absenteeism, unemployment, 
decreased output, reduced earning 
potential and lost working years. 
Alcohol consumption also causes 
intangible personal harm, the cost 
of which is challenging to estimate, 
but which includes pain, suboptimal 
quality of life, and the emotional 
and financial burden of alcohol 
misuse on families (PHE 2018). 
High-risk alcohol use and chronic 
pain have been shown to correlate 
in some of the following ways:
 » In terms of neuro-endocrine 
function, similar changes occur 
in the hypothalamic-pituitary-
adrenal axis and reward pathways 
(Elman and Borsook 2016). 
 » Behaviourally, people with 
chronic pain and high-risk alcohol 
use tend to exhibit maladaptive 
behaviours that exacerbate their 
condition. For example, people 
with high-risk alcohol use tend to 
continue to consume alcohol to 
alleviate negative moods (Baker 
et al 2004), while people who 
experience chronic pain tend to 
exhibit hypervigilant avoidance 
of pain triggers, for example by 
adopting unhealthy postures or 
overusing medicines, which in 
turn can prolong the experience 
of chronic pain (Vlaeyen and 
Linton 2000). 
 » In terms of co-morbidities, high-
risk alcohol use and chronic 
pain are associated with higher 
rates of anxiety disorders and 
post-traumatic stress disorder 
compared with the general 
population (Kroenke et al 2013). 
Allostatic load
McEwen and Stellar (1993) coined 
the term ‘allostatic load’ to describe 
the accumulated strain experienced 
by the body in its attempt to 
maintain homeostasis while exposed 
to repeated or chronic stress. 
Exposure to an external stress 
factor raises the blood pressure; 
however, following the removal of 
a stress factor, the blood pressure 
does not immediately return to 
baseline and remains elevated for 
some time. Exposure to chronic 
stress therefore leads to chronically 
elevated blood pressure, as well as 
persistent underlying changes in 
hormone levels. 
Neurological research has 
proposed that people who are 
addicted to substances such as 
alcohol have an elevated allostatic 
load and a chronic alteration in 
their neuro-endocrine function due 
to the stress of repeated substance 
misuse. This allostatic load is 
increased further by the stresses 
involved in withdrawal and relapse 
(Egli et al 2012), meaning that the 
individual’s normal neuro-endocrine 
function is dysregulated, resulting 
in reduced levels of dopamine and 
elevated levels of corticotropin-
releasing hormone. These hormonal 
imbalances are associated with 
feelings of depression. In people 
who are addicted to substances such 
as alcohol, attempting to relieve the 
negative feelings caused by these 
hormonal changes is thought to 
contribute to the drive to continue 
consuming alcohol (Koob and Le 
Moal 2001). 
It has also been observed that 
pain results in an overall long-
term decrease in dopamine levels 
(Taylor et al 2015). In addition, 
neuropathic pain in rats has been 
shown to generate hormonal 
changes, which are hypothesised 
to also occur in humans (Sagheddu 
et al 2015). Based on the similarities 
between chronic pain and alcohol 
dependence in terms of hormonal 
activity and behavioural responses, 
Egli et al (2012) proposed that 
alcohol dependence should be 
regarded as a chronic pain disorder. 
In addition, Egli et al (2012) also 
postulated that a higher number 
of episodes of withdrawal from 
alcohol in the past is likely to 
produce a greater allostatic load 
and therefore a higher likelihood  
of neuropathic pain. 
Medically assisted 
detoxification
People who are dependent on 
alcohol can develop alcohol 
withdrawal syndrome if they 
suddenly stop or reduce their 
intake. Symptoms include sweats, 
shakes, anxiety and possibly 
seizures (NICE 2011). Symptoms 
known collectively as delirium 
tremens and which include acute 
delirium, agitation, hallucinations, 
autonomic hyperactivity and 
tachycardia, can occur in 
approximately 5-10% of those 
who develop alcohol withdrawal 
syndrome (American Psychiatric 
Association 2013). Because of 
these risks, alcohol withdrawal 
syndrome must be managed 
promptly if it develops in hospital, 
using a process of medically assisted 
detoxification. Usually, this is 
done by administering a gradually 
reducing dose of chlordiazepoxide 
hydrochloride, a benzodiazepine 
drug given to effectively ‘replace’ 
the alcohol in neuronal receptors 
throughout the body, thus 
minimising any withdrawal 
symptoms. Simultaneously, regular 
vitamin B infusions should be 
started in the emergency department 
(ED) to prevent any alcohol-related 
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dementias associated with alcohol 
withdrawal syndrome, followed by 
a long-term course of oral vitamin B 
complex to reduce neuropathy over 
time (Peters et al 2006).
Various studies have been 
undertaken into the pain 
experienced by people undergoing 
detoxification from alcohol 
(Larson et al 2007, Witkiewitz 
et al 2015, Jakubczyk et al 2016). 
However, these studies did not use 
control groups, did not investigate 
neuropathic pain symptoms and did 
not consider participants’ history of 
detoxification. Also, research into 
the association between alcohol 
and pain has typically compared 
people with high-risk alcohol use 
with those who are not consuming 
alcohol to similar levels (Kim et al 
2013, Larance et al 2016), rather 
than differentiating between people 
with high-risk alcohol use according 
to their history of detoxification. 
This means that the influence of 
previous detoxification and relapse 
on neuropathic pain symptoms 
has not been isolated as a specific 
area of study. 
This study was inspired by the 
untested theory that allostatic 
load increases according to the 
number of episodes of withdrawal 
from alcohol experienced by an 
individual. Therefore, people 
with a higher number of episodes 
of withdrawal from alcohol are 
theorised to be more likely to 
experience neuropathic pain upon 
withdrawal, compared to people 
with fewer or no previous episodes 
of withdrawal (Egli et al 2012).
Aim
To investigate the presence of 
neuropathic pain upon withdrawal 
from alcohol, in people with high-
risk alcohol use, with or without 




This study used a quasi-
experimental observational cross-
sectional design to explore the 
presence of neuropathic pain in 
two groups of hospitalised patients 
with high-risk alcohol use: one 
group with a history of medically 
assisted detoxification and the 
other group with no history of 
medically assisted detoxification. 
The hypothesis was that a history of 
detoxification would correlate with 
neuropathic pain. 
Recruitment
The study population comprised 
a convenience sample recruited from 
adults in the ED at one hospital in 
London, England who had been 
identified as consuming alcohol 
to high-risk levels. All members of 
the study population presented to 
the ED where alcohol screening 
was routinely practised during 
triage and clerking. Patients were 
identified as high-risk consumers 
of alcohol, by a score of 3 or more 
on the Fast Alcohol Screening Test 
(FAST) (Hodgson et al 2002), which 
is used to identify people who 
require treatment for alcohol use. It 
comprises a four-item questionnaire 
derived from the World Health 
Organization’s alcohol use disorders 
identification test (AUDIT) 
questionnaire (Babor et al 2001). 
A FAST score of 3 or more has 
been demonstrated to have >90% 
sensitivity for identifying high-risk 
alcohol use. Following the FAST 
screening, eligible patients were 
referred to the substance misuse 
team for a brief intervention 
involving structured feedback and 
motivational advice, and invited 
to participate in this study. Only 
patients who were subsequently 
admitted to the hospital took part. 
The reasons for their admission to 
the hospital were not necessarily 
linked to high-risk alcohol use and 
included other conditions such as 
trauma or sepsis.
Data collection and analysis
With the participants’ consent, data 
were retrieved from their medical 
notes including their age, gender, 
ethnicity, daily alcohol consumption, 
frequency of alcohol use, years of 
alcohol use, smoking status, use of 
illicit drugs, use of analgesics, ED 
attendances in the past 24 months 
and number of previous medical 
assisted detoxifications. When 
the information was missing from 
the medical notes, the researcher 
(IW) directly asked participants to 
provide it. 
On day six of their admission to 
the general hospital, participants 
were asked to:
 » Self-rate their pain on four 
separate time-specific numerical 
pain rating scales (British Pain 
Society 2006).
 » Complete the Identification 
of Pain Questionnaire (IDPQ) 
(Portenoy 2006). 
The four numerical pain rating 
scales were used to assess the 
participants’ pain intensity ‘now’, 
pain intensity ‘average over the 
last week’, pain distress ‘now’, and 
pain distress ‘average over the last 
week’ (British Pain Society 2006). 
Points on the pain scales ranged 
from 0 (‘absent’) to 10 (‘extreme’) 
with gradations of 0.5. In line with 
previous research, a total pain score 
was calculated by summing the four 
scores, giving a total score of 0-40 
points (Galer et al 2002, Jensen and 
Karoly 2011). Numerical rating 
scales have been consistently used 
in research and clinical practice, 
since they have high validity and 
reliability in both literate and 
illiterate patients (Jensen and 
Karoly 2011). 
The IDPQ is used to identify 
neuropathic pain specifically 
(Portenoy 2006). It comprises six 
questions answered by ‘yes’ or 
‘no’ regarding the patient’s pain 
experience over the past week. It 
asks whether the pain feels like  
‘pins and needles’, a hot and/or 
burning sensation, numbness,  
and/or an electric shock; whether 
the sensation of pain is exacerbated 
by the touch of clothing or bed 
sheets; and whether pain is limited 
to the joints (Portenoy 2006). An 
answer of ‘yes’ scores one point, 
with the exception of the question 
‘Is pain limited to the joints?’, in 
which a response of ‘yes’ incurs 
a score of minus one. An IDPQ 
score of 3 or more suggests the 
presence of neuropathic pain  
and people with a score of 
3 or more are described as 
‘IDPQ-positive’. 
In this study, participants’ IDPQ 
scores were tested by chi-square 
and the potential influence of 
other variables was tested by 
analysis of variance (ANOVA) 
or chi-square. For factors where 
there were statistically significant 
differences between groups, an 
ANOVA could not be undertaken 
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Participants
Between February and July 2017, 
72 people who presented to the 
ED of one hospital in London and 
were subsequently admitted to 
the hospital where the study was 
conducted were identified as having 
a FAST score of 3 or more and 
recruited to the study. The drugs 
administered during medically 
assisted alcohol detoxification can 
have an analgesic effect, as can 
alcohol itself (Jochum et al 2010, 
Thompson et al 2017). Therefore, 
before participating in the study, 
participants were required to be 
abstinent from alcohol, while any 
medical assisted detoxification 
programme undertaken during their 
hospital admission was required to 
be completed. 
Among the 72 participants 
initially recruited, 42 individuals 
were discharged before day six of 
their admission, when they would 
have been asked to complete the 
four numerical pain rating scales 
and the IDPQ, or did not complete 
the scales despite receiving support 
to do so. The study was therefore 
conducted using a sample of  
30 participants (18 men, 12 women; 
mean age=51.6 years, standard 
deviation=10.9). 
Patients who were known 
to have undergone previous 
medically assisted detoxifications 
at the hospital, or who described 
and/or self-reported a previous 
detoxification, were allocated 
into the ‘history of detoxification’ 
group; the remaining patients were 
allocated to the ‘no history of 
detoxification’ group.
Ethics
The study was approved by the 
relevant NHS trust and received 
approval from the Research Ethics 
Panel at the Psychology Department 
of the University of Greenwich, 
London. Participants’ anonymity 
was preserved by assigning 
a number to each participant’s 
data, while any details that could 
have led to identification of the 
participants were kept in a locked 
file by the treating healthcare team. 
Participants received an information 
sheet detailing the aim of the study 
and the support available locally 
for managing high-risk alcohol use 
and chronic pain. Before completing 
the pain scales and questionnaire, 
participants were asked to sign 
a consent form, which explained 
that they could withdraw from the 
study at any point. 
Results
Of the 30 participants, 13 were 
allocated to the ‘no history of 
detoxification’ group, and 17 
were allocated to the ‘history 
of detoxification’ group. There 
was no significant difference 
between groups in the number of 
patients who had required medical 
assisted detoxification during their 
latest admission. 
Table 1 shows participants’ 
demographic and clinical data, 
total pain scores and IDPQ 
status according to history of 
Table 1. Participants’ demographic and clinical data, total pain score and IDPQ status according to  
history of detoxification
No history of detoxification 
(n=13)
History of detoxification (n=17) P value*
Mean age 54.5 years (n=13, range=30-70 
years, SD=10.5)
46.8 years (n=17, range=37-64 
years, SD=9.0)
0.03 (statistically significant)
Gender 6 women, 7 men (n=13) 6 women, 11 men (n=17) 0.55
Mean number of daily alcohol 
units†
18.4 units (n=8, SD=6.7) 33.1 units (n=13, SD=19.3) 0.05 (statistically significant)
Mean number of years of alcohol 
use
10.2 years (n=8, SD=13.7) 8.9 years (n=14, SD=8.3) 0.28
Mean number of ED attendances 
in the past 24 months
1.8 (n=13, SD=1.9) 8.1 (n=17, SD=9.3) 0.01 (statistically significant)
Chronic pain diagnosis‡ (yes/no) 3/9 (n=12) 5/10 (n=15) 0.64
Detoxification undertaken during 
hospital stay (yes/no)
5/7 (n=12) 9/6 (n=15) 0.34
Mean total pain score§ 16.11 points (n=13, SD=8.7) 19.27 points (n=17, SD=11.90) 0.43
IDPQ positive (yes/no) 1/12 (n=13) 8/9 (n=17) 0.04 (statistically significant)
ED = emergency department; IDPQ = Identification of Pain Questionnaire; SD = standard deviation
* Threshold for statistical significance: P<0.05
† Unit of alcohol defined as per Drinkaware (2021)
‡ Presence of a diagnosis of chronic pain determined by checking participants’ past medical history in their medical notes
§ Total pain score=0-40 points. Calculated by summing participants’ scores on four numerical rating scales from 0-10 (assessing pain intensity ‘now’, pain intensity ‘average over the 
last week’, pain distress ‘now’ and pain distress ‘average over the last week’, respectively)
 IDPQ positive = score of 3 or more on the IDPQ indicating presence of neuropathic pain
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detoxification. Participants’ 
medical notes were not always clear 
and comprehensive, and not all 
participants were able or willing to 
answer all questions, which explains 
the variations in respondent 
numbers that can be seen in Table 1. 
All data were normally 
distributed. In the ‘history of 
detoxification’ group, 47% of 
participants (eight out of 17) 
were IDPQ-positive (score of 3 
or more on the IDPQ indicating 
the presence of neuropathic pain), 
compared with 8% of participants 
(one out of 13) in the ‘no history 
of detoxification’ group. A chi-
square test showed that there was 
a significantly higher likelihood 
for participants with a history 
of detoxification to experience 
neuropathic pain (x²(1)=5.44, 
P=0.02). Given the small sample 
size, a Fisher’s exact test was 
also undertaken. It also showed 
a statistically significant association 
between history of detoxification 
and presence of neuropathic pain, 
but was less pronounced than with 
the chi-square test (P=0.042 for the 
Fisher’s exact test versus P=0.02 for 
the chi-square test). 
Statistically significant differences 
between the two groups were found 
for mean age (H(1, n=30)=5.22, 
P=0.03), mean number of daily 
alcohol units (H(1, n=21)=3.78, 
P=0.05) and mean number 
of ED attendances in the past 
24 months (H(1, n=30)=6.63, 
P=0.01). Participants in the 
‘history of detoxification’ group 
were significantly younger, drank 
significantly more units of alcohol 
per day and had had significantly 
more ED attendances in the 
previous 24 months compared with 
participants in the ‘no history of 
detoxification’ group. 
There were no other statistically 
significant differences between the 
groups, including no statistically 
significant difference in total 
pain scores. 
Discussion
In this study of 30 hospitalised 
adults with high-risk alcohol use, 
participants who had previously 
undergone medically assisted 
detoxification were more likely 
to experience neuropathic pain 
upon withdrawal than those who 
had not previously undergone 
medically assisted detoxification. 
Neuropathic pain has been 
associated with increasing age 
(Bouhassira et al 2008); however, 
in this study, participants in 
the ‘history of detoxification’ 
group were significantly younger 
than those in the ‘no history of 
detoxification’ group. 
Participants in the ‘no history 
of detoxification’ group drank 
approximately 50% less alcohol 
(18.4 daily alcohol units) than 
participants in the ‘history of 
detoxification’ group (33.1 daily 
alcohol units). However, there 
was no significant difference in the 
number of patients who required 
detoxification during the admission 
being studied, suggesting that this 
did not influence the significant 
relationship between historic 
detoxifications and neuropathic 
symptoms. It is possible that the 
higher daily alcohol intake in the 
‘history of detoxification’ group 
resulted in a higher occurrence of 
neuropathic pain, in accordance 
with recent understanding of the 
causes of alcohol-related peripheral 
neuropathy (Mellion et al 2011). 
The study results support the 
authors’ hypothesis that allostatic 
load is increased in people with 
a higher number of episodes of 
withdrawal from alcohol, and 
that they are likely to experience 
neuropathic pain upon withdrawal. 
However, the study was not 
designed to determine whether any 
potential difference in allostatic  
load between participants 
influenced the results, since 
measuring hormonal activity in  
the brain was not feasible. 
Nursing implications
Pain can trigger relapse following 
alcohol withdrawal treatment 
(Jakubczyk et al 2016), and 
people with a history of alcohol 
dependence are at increased risk 
of addiction to analgesics such as 
opioids (Cragg et al 2019). Nurses 
should be aware that neuropathic 
pain may be more likely in 
people with high-risk alcohol use 
who have previously undergone 
medically assisted detoxification. 
Understanding that previous 
detoxification may increase the 
risk of neuropathic pain means 
that nurses can prepare themselves 
to assess, discuss and assist in 
managing neuropathic pain for 
people recovering from high-risk 
alcohol use, ultimately enhancing 
patient experience and potentially 
improving outcomes. 
By discussing neuropathic pain 
with their patients, nurses can 
direct those recovering from high-
risk alcohol use to available pain 
management support in a timely 
manner. An assessment of pain 
should include questions about 
the site of the pain, as well as the 
duration and nature of the pain. 
Nurses can undertake online 
training in this type of assessment, 
which is provided by Health 
Education England, the Faculty of 
Pain Medicine of the Royal College 
of Anaesthetists and the British Pain 
Society, and which counts towards 
nurses’ revalidation (portal.e-lfh.
org.uk/Component/Details/391439). 
If a patient describes pain 
symptoms that have been present 
for more than three months, they 
can be referred to a local chronic 
pain clinic. These clinics often 
use a multidisciplinary approach 
incorporating psychology and 
physiotherapy approaches to 
set realistic goals and assist the 
individual to identify coping 
strategies that do not rely on 
alcohol. This is important given 
the links between pain, relapse 
into alcohol use and addiction to 
analgesics (Jakubczyk et al 2016, 
Cragg et al 2019).
When people with high-risk 
alcohol use and chronic pain 
are admitted to hospital, nurses 
should consider this as a ‘teachable 
moment’ (Jivraj et al 2020). 
Outcomes in these patient groups 
are often based on patients’ own 
self-efficacy of pain, which means 
that those who have a significant 
belief in their ability to change will 
experience improved outcomes 
compared with those who have 
less belief in their ability to change 
(Martinez-Calderon et al 2018). 
To support self-efficacy, nurses 
should be prepared to provide the 
patient with positive affirmation 
at every opportunity, for example 
drawing attention to their ability to 
manage without alcohol. Evidence 
also suggests that nurses should 
encourage these patients to ‘pace’ 
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activities such as taking exercise, 
for example, so they do not take 
on too much, yet at the same time 
ensuring that they do not avoid 
activity altogether (McCracken and 
Samuel 2007). 
Nurses should also encourage 
patients to book a GP appointment 
following discharge, and this 
advice should be included in any 
discharge summaries. GPs are able 
to refer patients to pain teams in 
the community so that patients can 
receive psychological therapy, such 
as cognitive behavioural therapy, 
to assist in the management of 
neuropathic pain. GPs are also able 
to ensure the ongoing prescription 
of vitamin B complex for patients 
with a history of high-risk alcohol 
use, which will contribute to the 
management of any neuropathy 
(Peters et al 2006).
Many common drugs 
administered for neuropathic 
pain such as gabapentin and 
amitriptyline hydrochloride are 
addictive, yet need to be taken 
regularly for long periods of time 
if they are to be effective (NICE 
2013, PHE 2019, Taylor et al 
2019). If these drugs are prescribed 
in hospital, it is important for 
the nurse to ensure that patients 
understand that they must be 
reviewed regularly by their GP 
following discharge. 
The training in neuropathic pain 
or high-risk alcohol use available to 
nurses can vary, but many trusts will 
have acute pain teams and alcohol 
teams with specialist nurses who 
can be ‘shadowed’. There is also 
accredited training available online 
for brief alcohol interventions, 
which provide techniques for 
motivational conversations with 
this client group (www.e-lfh.org.uk/
programmes/alcohol). In addition, 
the organisation Live Well with Pain 
provides pain management advice 
for clinicians, including resources 
for patient self-management 
(livewellwithpain.co.uk/resources/
resources-for-your-patients).
In this study, there was no 
statistically significant difference 
between the two groups in terms of 
the likelihood of patients requiring 
medically assisted detoxification 
during their hospital stay, so the 
implications of the study are also 
valid in settings that do not provide 
detoxification. This also means 
that nurses can assess, discuss, 
monitor and manage neuropathic 
pain in patients before they undergo 
potential detoxification.
Limitations and further research
There were limitations to this 
study. The opportunistic nature of 
recruitment may have contributed 
to the fact that members of one of 
the two groups drank significantly 
less alcohol than the other. Also, the 
sample size was small, particularly 
in terms of conducting a chi-
square test. It is acknowledged that 
participants had been admitted 
to various wards at various times 
and for different conditions, so 
there may have been variations in 
treatment and care that could have 
influenced the results. Caution is 
therefore required when interpreting 
the results. 
To control for variations 
in treatment and care, further 
research could be conducted in 
a sample of participants recruited 
from a substance misuse service 
or inpatient detoxification unit. 
Further research in a larger sample 
would provide more reliable results. 
A longer study with a follow-
up period would be valuable to 
determine whether and to what 
extent neuropathic pain persists 
after alcohol withdrawal over time. 
However, drop-out rates tend to 
be high and effective follow up can 
be an issue in people with high-risk 
alcohol use (Gill et al 2016). 
Conclusion
It had been hypothesised that 
a higher number of episodes of 
medically assisted detoxification 
increased the likelihood of people 
who engaged in high-risk alcohol 
use experiencing neuropathic pain. 
This study provides evidence that 
neuropathic pain is more likely 
in those who have undergone 
previous detoxification compared 
with those who have not. It also 
provides guidance for nurses on 
pain assessment, brief interventions 
and referral to specialists when 
caring for people with high-risk 
alcohol use. These measures mean 
that nurses can be better prepared 
to assess, discuss and manage 
neuropathic pain before patients 
undergo potential detoxification, 
ultimately enhancing patient 
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